scholarly journals Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

2018 ◽  
Vol 29 ◽  
pp. viii58-viii59
Author(s):  
M.V. Dieci ◽  
P.F. Conte ◽  
G. Bisagni ◽  
A.A. Brandes ◽  
A. Frassoldati ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Tumor Infiltrating Lymphocytes ◽  
Independent Prognostic Factor ◽  
Breast Cancer Patients ◽  
Her2 Breast Cancer ◽  
Infiltrating Lymphocytes

PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 544-544 ◽  
Author(s):  
Pier Franco Conte ◽  
Gaia Griguolo ◽  
Maria Vittoria Dieci ◽  
Giancarlo Bisagni ◽  
Alba Ariela Brandes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Prognostic Value ◽  
Independent Prognostic Factor ◽  
Phase Iii ◽  
Breast Cancer Patients ◽  
Pam50 Subtype

544 Background: We investigated the prognostic role of the PAM50 HER2-enriched (HER2-E) subtype in HER2+ early breast cancer enrolled in the randomized Phase III ShortHER trial. Methods: The ShortHER study randomized 1254 HER2+ early breast cancer patients to receive 9 weeks vs 1 year of adjuvant trastuzumab combined with chemotherapy. Gene expression measured using nCounter platform was available for 438 surgical samples. Intrinsic subtyping was determined using the research-based PAM50 predictor. Metastasis-free survival (MFS) was calculated from randomization to distant disease recurrence or death (median follow up 72 months). Uni- and multi-variable analysis were performed using Cox models. Results: PAM50 subtype distribution was: HER2-E 53% (N = 233), Luminal A 20% (N = 87), Luminal B 10% (N = 43), Normal-like 11% (N = 48) and Basal-like 6% (N = 27). HER2-E subtype was associated with hormone receptor-negative status (p < 0.001) and TILs ≥20% (p < 0.001), but not with stage and age ( < or ≥60 yrs). HER2-E subtype was associated with worse MFS vs other PAM50 subtypes overall (HR 2.78, p = 0.001), in the short (HR 2.24, p = 0.046), and in the long arm (HR 4.04, p = 0.011). Multivariable Cox model confirmed the independent prognostic value of HER2-E subtype (Table). HER2-E subtype added significant prognostic value on top of clinicopathological variables (Likelihood ratio test p < 0.001). Conclusions: HER2-E intrinsic subtype is an independent prognostic factor for HER2+ early breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Integration of PAM50 subtype in prognostic algorithms can help refine risk stratification. These findings warrant independent validation. Clinical trial information: NCT00629278. [Table: see text]

scholarly journals Comparison of Tumor - Infiltrating Lymphocytes Between Primary and Metastatic Tumors in Her2+ and HER2-Breast Cancer Patients

2018 ◽  
Vol 69 (11) ◽  
pp. 3133-3137 ◽  
Author(s):  
Claudia Mehedintu ◽  
Elvira Bratila ◽  
Costin Berceanu ◽  
Monica Mihaela Cirstoiu ◽  
Ramona Ileana Barac ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Growth Factor Receptor ◽  
Tumor Infiltrating Lymphocytes ◽  
Breast Cancer Patients ◽  
Metastatic Tumors ◽  
Tumor Biopsy ◽  
Her2 Breast Cancer ◽  
Infiltrating Lymphocytes ◽  
The Impact

The impact of tumor infiltrating lymphocytes (TILs) on survival was confirmed in various cancer types. Our study aims to investigate the prognostic role of TILs on survival in patients with primary and metastatic tumors in breast cancer patients. We retrospectively identified 29 patients with human epidermal growth factor receptor - 2 (HER2+) and HER2 - early breast cancer diagnosed between 2012 and 2018 at Institute of Oncology Prof. Dr. Al. Trestioreanu Bucharest and who subsequently experienced regional or distant recurrence confirmed by tumor biopsy/resection.

Sign in / Sign up

Export Citation Format

Share Document